Singapore markets closed
  • Straits Times Index

    3,166.27
    -55.25 (-1.72%)
     
  • Nikkei

    28,751.62
    -747.66 (-2.53%)
     
  • Hang Seng

    24,080.52
    -659.64 (-2.67%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • BTC-USD

    54,750.82
    +509.74 (+0.94%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • FTSE Bursa Malaysia

    1,512.22
    -5.38 (-0.35%)
     
  • Jakarta Composite Index

    6,561.55
    -137.79 (-2.06%)
     
  • PSE Index

    7,278.44
    -90.83 (-1.23%)
     

Novartis posts first-quarter sales, profit beat as COVID-19 spurs prescriptions

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

ZURICH (Reuters) - Swiss drugmaker Novartis reported rising first-quarter sales and profit that beat analyst expectations and confirmed its 2020 targets as the coronavirus pandemic prompted patients to stock up on their prescriptions in advance.

"COVID-19 did result in increased forward purchasing by customers, including at the patient level, as some patients filled prescriptions to cover a longer period of time," Novartis said on Tuesday.

Core net income rose to $3.55 billion, from $2.8 billion in 2019 and compared to the average analyst forecast in a Refinitiv poll of $3.17 billion. Sales rose to $12.3 billion from $11.1 billion in the year-ago period, also above the poll average of $12 billion.

Net income rose 16% to $2.2 billion. The Basel-based company at this time still expects revenue to grow at a mid- to high-single-digit percentage rate, with core operating profit growth even faster at a high-single to low-double-digit rate.

Novartis said the new coronavirus epidemic did not disrupt its underlying operations, but that significant advance buying by patients concerned about access to their medicines helped boost revenue and profits significantly in the first three months of the year.

"Excluding COVID-19 related forward purchases, we estimate sales growth would have been approximately 9%," the company said, less than the 13% growth it reported at constant exchange rates.

(Reporting by John Miller; Editing by Michael Shields)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting